{"id":"W3204380660","doi":"10.1016/j.jtho.2021.09.014","title":"IMpower150 Final Exploratory Analyses for Atezolizumab Plus Bevacizumab and Chemotherapy in Key NSCLC Patient Subgroups With EGFR Mutations or Metastases in the Liver or Brain","year":2021,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Brain Metastases and Treatment","field":"Medicine","cited_by":303,"is_retracted":false,"has_abstract":false,"ca_institutions":"","funders":"Eli Lilly Japan; Chugai Pharmaceutical; Pfizer Japan; Merck Sharp and Dohme; Genentech; Eisai; Daiichi-Sankyo; Mirati Therapeutics; Clovis Oncology; Johnson and Johnson; Teva Pharmaceutical Industries; Les Laboratories Pierre Fabre; Boehringer Ingelheim Japan; Taiho Pharmaceutical; F. Hoffmann-La Roche; Takeda Pharmaceutical Company; AbbVie; Merck; Spectrum Pharmaceuticals; Bayer; Gilead Sciences; Roche; Celgene; Novartis; Exelixis; Sanofi; GlaxoSmithKline; Boehringer Ingelheim; Amgen; Incyte; Pfizer; Canadian Asian Studies Association; AstraZeneca; Ono Pharmaceutical; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Medicine; Atezolizumab; Bevacizumab; Carboplatin; Hazard ratio; Internal medicine; Oncology; Paclitaxel; Chemotherapy; Confidence interval; Gastroenterology; Cancer; Nivolumab; Cisplatin; Immunotherapy","routes":{"ca_aff":false,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":true},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008329223,0.0002044673,0.0007627468,0.000298634,0.00007729949,0.00003237549,0.00009701632,0.00009332303,0.0001807085],"category_scores_gemma":[0.0003888297,0.0001024415,0.000144657,0.0004987005,0.0001203464,0.0001633858,0.00002601182,0.0003094812,0.000001242289],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0004176819,"about_ca_system_score_gemma":0.001494099,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00004245264,"about_ca_topic_score_gemma":0.002481522,"domain_scores_codex":[0.9979485,0.0006121364,0.0006492907,0.0002271507,0.0002862962,0.0002766385],"domain_scores_gemma":[0.997618,0.001387663,0.0004153127,0.0002022339,0.0002593075,0.000117531],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.1267382,0.007811562,0.004401695,0.0005503616,0.002440328,0.05856907,0.03010977,0.0006565999,0.00113272,0.0002800007,0.00716932,0.7601404],"study_design_scores_gemma":[0.1350492,0.1595078,0.1397566,0.003055732,0.009295251,0.1075215,0.2044057,0.002874976,0.01542973,0.002033023,0.219287,0.001783514],"study_design_candidate":"design_other","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.981854,0.003103811,0.0009708856,0.01327809,0.00009049776,0.0005922361,0.00004691966,0.000005251424,0.00005837153],"genre_scores_gemma":[0.977309,0.0006378474,0.018852,0.002857265,0.0001004635,0.00007858177,0.00003374808,0.00002402071,0.0001070239],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.7583569,"threshold_uncertainty_score":0.4177444,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.09509215825979998,"score_gpt":0.4425816826641609,"score_spread":0.3474895244043609,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}